
Sign up to save your podcasts
Or
In episode 584, Mike and James invite Tina Korownyk back to the podcast to talk about the evidence for amyloid-targeting monoclonal antibodies in mild cognitive impairment or Alzheimer’s dementia. Unfortunately, the evidence shows these medications don’t seem to have a clinically important effect and do have some harms. Have a listen as we give you all the numbers so you will be able to properly discuss these medications with your patients.
Show notes
Tools for Practice
4.6
165165 ratings
In episode 584, Mike and James invite Tina Korownyk back to the podcast to talk about the evidence for amyloid-targeting monoclonal antibodies in mild cognitive impairment or Alzheimer’s dementia. Unfortunately, the evidence shows these medications don’t seem to have a clinically important effect and do have some harms. Have a listen as we give you all the numbers so you will be able to properly discuss these medications with your patients.
Show notes
Tools for Practice
114 Listeners
525 Listeners
487 Listeners
690 Listeners
285 Listeners
270 Listeners
255 Listeners
3,322 Listeners
1,090 Listeners
599 Listeners
184 Listeners
517 Listeners
243 Listeners
85 Listeners
362 Listeners